Oxybutynin Patent Expiration
Oxybutynin is Used for treating overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence. It was first introduced by Allergan Sales Llc
Oxybutynin Patents
Given below is the list of patents protecting Oxybutynin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Gelnique 3% | US7029694 | Compositions and methods for transdermal oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Gelnique 3% | US7179483 | Compositions and methods for transdermal oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Gelnique 3% | US7198801 | Formulations for transdermal or transmucosal application |
Jun 25, 2022
(Expired) | Allergan |
| Gelnique 3% | US8241662 | Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Oxytrol | US5601839 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr 26, 2015
(Expired) | Allergan |
| Oxytrol | US5834010 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr 26, 2015
(Expired) | Allergan |
| Oxytrol | US6743441 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Oxytrol | US7081249 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Oxytrol | US7081250 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Oxytrol | US7081251 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Oxytrol | US7081252 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Oxytrol | US7179483 | Compositions and methods for transdermal oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Oxytrol For Women | US5601839 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr 26, 2015
(Expired) | Abbvie |
| Oxytrol For Women | US5834010 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr 26, 2015
(Expired) | Abbvie |
| Oxytrol For Women | US6743441 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Abbvie |
| Oxytrol For Women | US7081249 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Abbvie |
| Oxytrol For Women | US7081250 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Abbvie |
| Oxytrol For Women | US7081251 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Abbvie |
| Oxytrol For Women | US7081252 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Abbvie |
| Oxytrol For Women | US7179483 | Compositions and methods for transdermal oxybutynin therapy |
Apr 26, 2020
(Expired) | Abbvie |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Oxybutynin Generics
Only one generic application has been filed for Oxybutynin.
Given below is the list of companies who have filed for Oxybutynin generic.
1. BARR LABS DIV TEVA
Barr Laboratories Inc Sub Teva Pharmaceuticals Usa has filed for 1 generic for Oxybutynin. Given below are the details of the strengths of this generic introduced by Barr Labs Div Teva.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.9MG/24HR | film, extended release | Discontinued | TRANSDERMAL | N/A | Mar 4, 2014 |